TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03405584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT01215565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent
Description: Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
Study: NCT02993757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.
Study: NCT01133847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive reading instruction
Description: Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive reading instruction
Description: Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
Study: NCT02993757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, SC injection at Month 1, 7 and 13, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
Description: 0.5 mL, IM injection at Day 0 and Month 6, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
Description: 0.5 mL, IM injection at Day 0 and Month 6, respectively.
Study: NCT04067700

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Invasive coronary treatment
Description: Coronary artery bypass surgery or percutaneous coronary intervention.
Study: NCT03207477

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual acuity measurement
Description: visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual acuity measurement
Description: visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
Study: NCT06199817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occupational therapies
Description: music, garden-soil and sports practices for individuals diagnosed with schizophrenic disorder
Study: NCT03919331

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)
Description: After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days
Study: NCT05216783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviews
Description: The qualitative research studies performed on the traumatic childbirth experiences indicated that the pregnant women's interaction and communication with the midwives were more effective than the medical intervention methods that were applied.
Study: NCT02886832

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prostate Health formulation
Study: NCT00259610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: varies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: varies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: varies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: varies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfasalazine
Description: varies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfasalazine
Description: varies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: varies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxychloroquine
Description: varies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: varies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: varies
Study: NCT01766596

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optical Coherence Tomography
Study: NCT00731627

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet a day for up to 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 40mg once a day for a maximum of 21 days
Study: NCT02518256

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lavage of the Cavum uteri and proximal fallopian tubes
Study: NCT01160315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin: intramusculAR injection every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate
Description: 5 mg/day per os until during chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethisterone acetate
Description: 5 mg/day per os until during chemotherapy
Study: NCT04926428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tPA
Description: Selectively catheter thrombolysis with alteplase in each main pulmonary
Study: NCT01185769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: 500 mg of tocotrienol will be administered after consumption of high fat diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: 500 mg of tocotrienol will be administered after consumption of low fat diet
Study: NCT02705586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
Study: NCT00148369

Intervention type: DRUG
Intervention: Safety observation
Description: Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
Study: NCT00117663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: temporary discontinuation of hormone therapy for 1 month
Description: temporary discontinuation of hormone replacement therapy for 1 month prior to screening mammogram.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: temporary discontinuation of hormone therapy for 2 months
Description: temporary discontinuation of hormone replacement therapy for 2 months prior to screening mammogram
Study: NCT02387099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 weeks Dose Induction of Everolimus
Description: Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 weeks Conventional Everolimus Dosing
Description: Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio
Study: NCT01133847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: Nine sessions on parenting a child with ADHD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: Nine sessions on parenting a child with ADHD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed Salt Amphetamine
Description: Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed Salt Amphetamine
Description: Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Appropriate dosage to be individually determined; daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Appropriate dosage to be individually determined; daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Appropriate dosage to be individually determined; daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Appropriate dosage to be individually determined; daily for 16 weeks
Study: NCT03892096

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-based cell-free cfDNA qPCR assay
Description: Up to 30mL of blood via venipuncture
Study: NCT00799422

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Easy Rub
Description: Commercially marketed contact lens solution for contact lens care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus
Description: Commercially marketed contact lens solution for contact lens care
Study: NCT02387099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
Description: All patients will receive open label Everolimus with Exemestane for 21 weeks according to label

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
Description: All patients will receive open label Everolimus with Exemestane for 21 weeks according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care after 24 weeks
Description: It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care after 24 weeks
Description: It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
Study: NCT02613676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin screening
Description: Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care (Visual inspection)
Description: Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
Study: NCT03311113

Intervention type: OTHER
Intervention: Drug adherence questionnaire
Description: Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
Study: NCT01454661

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LGG
Description: Lactobacillus rhamnosus GG 10E9 cfu / day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LGG
Description: Lactobacillus rhamnosus GG 10E9 cfu / day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LGG+Bb-12
Description: A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LGG+Bb-12
Description: A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose is used as placebo.
Study: NCT01464736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical training
Description: For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical training
Description: For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
Study: NCT00004266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study: NCT03760835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
Description: Treatment of congenital adrenal hyperplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
Description: Treatment of congenital adrenal hyperplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual release hydrocortisone (plenadren)
Description: Treatment of congenital adrenal hyperplasia
Study: NCT06509841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation treatment
Description: Adopting conventional rehabilitation training methods for TSCI patients, including: ① posture training; ② Joint rehabilitation training; ③ Breathing training; ④ Muscle strength training, 7 times a week, with continuous treatment for 4 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional rehabilitation treatment
Description: Adopting conventional rehabilitation training methods for TSCI patients, including: ① posture training; ② Joint rehabilitation training; ③ Breathing training; ④ Muscle strength training, 7 times a week, with continuous treatment for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment rehabilitation
Description: Routine rehabilitation treatment combined with acupuncture and moxibustion treatment, the acupuncture measures taken are mainly Dumai points. Once a day. 5 times a week, continuous treatment for 4 weeks.
Study: NCT06240663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups complete the exercise intervention identically, but one is in the fasted state and one is in the fed state.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups complete the exercise intervention identically, but one is in the fasted state and one is in the fed state.
Study: NCT01629186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPO with Nose-close and Abdomen-compression
Description: Infants with body weight (BW) \<5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) \<80 beats/min or oxygen saturation (SpO2) \<85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
Study: NCT00102063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole tablet, 10 mg
Description: Aripiprazole tablet 10 mg po qd x 42 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole tablet, 30 mg
Description: Aripiprazole tablet 30 mg po qd x 42 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet po qd x 42 days
Study: NCT02245581

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVV-guided fluid management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVP-guided fluid management
Study: NCT00413595

Intervention type: OTHER
Intervention: No intervention
Description: Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
Study: NCT02655835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Mindfulness Meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access
Study: NCT03707041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P218 (1000 mg) Oral Capsules
Description: 1000 mg P218 (4 x 250 mg capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P218 (1000 mg) Oral Capsules
Description: 1000 mg P218 (4 x 250 mg capsules)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsules
Description: Placebo capsules matched to the P218 capsules with regard to appearance and taste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsules
Description: Placebo capsules matched to the P218 capsules with regard to appearance and taste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsules
Description: Placebo capsules matched to the P218 capsules with regard to appearance and taste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P218 (100 mg) Oral Capsules
Description: 100 mg P218 (2 x 50 mg capsules)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PfSPZ Challenge
Description: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
Study: NCT03123978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Given PO
Study: NCT03392740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
Study: NCT00094094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
Study: NCT01795079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.